Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19

Acute Respiratory Distress Syndrome Clinical Trial

Official title:

Safety and Efficacy of Intravenous Infusion of Wharton's Jelly Derived Mesenchymal Stem Cell Plus Standard Therapy for the Treatment of Patients With Acute Respiratory Distress Syndrome Diagnosis Due to COVID 19: A Randomized Controlled Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04390152
• Other study ID #: BIOXSOMCOV001
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: January 13, 2020
• Est. completion date: April 2022

Study information

• Verified date: January 2021
• Source: BioXcellerator
• Contact: Alfredo Hernandez-Ruiz, MSc
• Phone: +5745699999
• Email: ahernandez[@]clinicasomer.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Recent COVID 19 pandemic has overwhelmed health services all around the world, and humanity has yet to find a cure or a vaccine for the treatment of patients, mainly the severe ones, who pose a therapeutic challenge to healthcare professionals given the paucity of information we have regarding SARS-CoV-2 pathogenesis.

Recently, reports mainly from China from patients treated with mesenchymal stem cells have shown promise in accelerating recovery, even in the critically ill and the therapy has sustained an increase in research because of it's powerful immunomodulatory effects, making it and interesting alternative in patients with lung and systemic inflammation.

These effects could help treat a lot of patients and improve their outcomes, reason why phase I/II studies are needed to show their safety and experimental efficacy.

Description:

SARS-CoV-2, virus culprit of the COVID 19 that emerged in China, has become now a worldwide problem, with more than three million cases al around the world as reported by the World Health Organization. This situation has put health systems under extreme pressure, being overwhelmed be the amount of patients requiring attention.

Around 5% of patients will require ICU internation, due to severe lung inflammation giving rise to Acute Respiratory Distress Syndrome (ARDS) and a cytokine storm that ultimately affects other organs. In this group, mortality can be as high as 40%.

Mesenchymal stem cells (MSC) have shown great immunomodulatory effects, and are used in other inflammatory conditions as autoimmune diseases, being safe and preliminary effective in improving patients health status. They exert their effect via paracrine and autocrine pathways and have been shown to reduce IL-1, IL-6, Tumor necrosis factor alpha and increase IL-10 in COVID 19 patients. One of the greater advantages of the MSC is that they express no Major Histocompatibility Complex, reducing the risk of host immune reaction.

Given their immunomodulatory effects, research in this topic showing their safety and experimental efficacy are needed, as therapies for severe patients are lacking. Patients, researchers and data analysts will be blinded, and ARDS patients will be randomly allocated in standard therapy plus MSC arm or standard therapy alone to answer these questions.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: April 2022
• Est. primary completion date: December 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• SARS-CoV-2 positive Real Time - Polymerase Chain Reaction

• Moderate to severe Acute respiratory distress syndrome according to Murray classification.

• PaO2/FiO2 less than 200 mmHg.

• Within 36 hours of orotracheal intubation.

• Absence of response with previous standard therapy.

• Willing to participate in the study expressed by patient or responsible caregiver.

• Not being in other clinical trial.

Exclusion Criteria:

• Current pregnancy.

• Cardiac rhythm abnormalities with instability.

• Acute congestive heart failure/cardiogenic shock.

• Severe comorbidities affecting mortality as defined by research group.

• Cancer history in the past 5 years.

• HIV, syphilis, hepatitis B or C.

• Concomitant use of immunosuppressive therapy with contraindication to MSC.

• Fivefold elevation of liver enzymes (ALT, AST).

• Chronic kidney disease with glomerular filtration rate below 30ml/min or dialytic needs.

Related Conditions & MeSH terms

• Acute Lung Injury
• Acute Respiratory Distress Syndrome
• Respiratory Distress Syndrome, Adult
• Respiratory Distress Syndrome, Newborn
• Syndrome

Intervention

Drug:
• Wharton's jelly derived Mesenchymal stem cells.
IV Wharton's jelly derived Mesenchymal stem cells, two doses
• Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
Standard therapy as per hospital protocol, hydroxychloroquine 400mg + Lopinavir/Ritonavir 400/100 or azithromycin 500mg and Placebo

Locations

Country	Name	City	State
Colombia	BioXcellerator	Medellin	Antioquia-CO
Colombia	Clinical Somer	Rionegro	Antioquia

Sponsors (2)

Lead Sponsor	Collaborator
BioXcellerator	Clinical Somer

Country where clinical trial is conducted

Colombia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Changes in 6 minute walk between groups	Evaluation of the effect of WJ-MSC in pulmonary function measured with 6 minute walk.; 6 minute walk is a test that gives information about pulmonary, cardiovascular and musculoskeletal functions. It measures the distance walked in 6 minutes in meters.	6 months
Other	Changes in Pulmonary Computed Tomography Scan between groups	Evaluation of the effect of WJ-MSC in pulmonary function with thoracic CT scan. CT scan gives information about lung parenchyma, showing acute and chronic changes related to the underlying condition. Radiologic findings will be compared mainly comparing percentage of patients with pulmonary fibrosis.	6 months
Other	Changes in Spirometry between groups	Evaluation of the effect of WJ-MSC in pulmonary function measured with spirometry, compared between the two groups. Spirometry gives information about lung volume and mobilization of air.; Main parameters to be measured in spirometry are Forced Vital Capacity, Forced Expiratory Volume in 1 second and relation between these two to define if there is obstruction or restriction of airflow.	6 months
Other	Changes in health related quality of life between groups	Evaluation of the effect of WJ-MSC in health related quality of life assessed by 36 Item Short Survey (SF-36).; SF 36 is a patient reported tool. Each question is rated from 0 to 100, being 100 the best score possible. The scores are then compared to a population defined median score.; Differences in global and specific scoring will be measured between groups.	6 months
Primary	Intergroup mortality difference with treatment	Evaluation of efficacy of WJ-MSC defined by mortality at 28 days of application.	28 days.
Secondary	Number of patients with treatment related adverse events	Safety evaluation of WJ-MSC describing and comparing incidence, type and severity of adverse events in both groups.	6 months.
Secondary	Difference in days of mechanical ventilation between groups	Evaluation of the effect of WJ-MSC in the time of mechanical ventilation compared between the two groups, as prolonged mechanical ventilation days are associated with higher complication risks as pneumonia, tracheostomy and death.	From ICU admission to 180 days.
Secondary	Median reduction of days of hospitalization	Evaluation of the effect of WJ-MSC in the time of hospitalization between the two groups as a measure of efficacy.	From hospital admission to 180 days.
Secondary	Median reduction of days of oxygen needs	Evaluation of the effect of WJ-MSC in the time of oxygen needs compared between the two groups as a measure of efficacy.	From hospital admission to 180 days.
Secondary	Difference between "Sequential Organ Failure Assessment" score between groups	"Sequential Organ Failure Assessment" (SOFA) score is a tool used to determine the beginning and evolution of multiorgan failure, ranging from 0 to 24, being 24 the worst scenario. It has been proven useful as an outcome predictor of mortality and ICU stay. The result is the addition of the evaluation of each organ or system. Effect of WJ-MSC in the SOFA score will be compared between the two groups.	Baseline to 7 days
Secondary	Difference between median Murray score between groups	Murray score is a tool used to classify lung injury. 0 = no lung injury, 0.1-2.5, mild to moderate lund injury, >2.5 Acute respiratory distress syndrome.; The effect of WJ-MSC in the Murray score will be compared between the two groups.	Baseline and 7 days
Secondary	Difference in APACHE II score between groups	APACHE II is a prognostic score based on 12 different items obtained in the first 24 hours of ICU admission. Its mainly used as a single measure, but some authors have used and described prediction usefulness with repeated measures. It ranges from 0 to 71 points. Higher scores are related to higher ICU mortality.; The effect of WJ-MSC in the APACHE II score will compared between the two groups.	Baseline and 7 days
Secondary	Difference in lymphocyte count between groups	Evaluation of the effect of WJ-MSC in lymphocyte count measured in absolute number/mm3.; These laboratory measures have been associated with COVID 19 severity.	baseline and 21 days or discharge
Secondary	Changes in C reactive protein concentration between groups	Evaluation of the effect of WJ-MSC in C reactive protein concentration between the two groups, measured in mg/dl.; Highest levels have been associated with COVID 19 severity and inflammation.	baseline and 21 days or discharge
Secondary	Changes in D dimer concentration	Evaluation of the effect of WJ-MSC in D dimer between the two groups, measured in micrograms Highest levels have been associated with COVID 19 severity and thromboembolic complications.	baseline and 21 days or discharge
Secondary	Changes in ferritin concentration	Evaluation of the effect of WJ-MSC in ferritin compared between the two groups, measured in nanograms/ml.; These laboratory measures have been associated with COVID 19 infection and severity.	baseline and 21 days or discharge
Secondary	Changes in lactate dehydrogenase concentration	Evaluation of the effect of WJ-MSC in LDH compared between the two groups, measured in units/liter.; These laboratory measures have been associated with COVID 19 infection and severity.	baseline and 21 days or discharge
Secondary	Impact on interleukin 6 concentrations between groups.	Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation.The effect of WJ-MSC in IL-6 will be compared between the two groups. It will be measured in picograms/ml.	Baseline and 7 days
Secondary	Impact on interleukin 8 concentrations between groups.	Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 8 will be compared between the two groups. It will be measured in picograms/ml.	Baseline and 7 days
Secondary	Impact on interleukin 10 concentrations between groups.	Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in IL 10 will be compared between the two groups. It will be measured in picograms/ml.	Baseline and 7 days
Secondary	Impact on tumor necrosis factor alpha concentrations between groups.	Cytokines are biomarkers of inflammation or inflammatory activity in the human body. Changes in this profile give information about underlying process of inflammation. The effect of WJ-MSC in TNF alpha will be compared between the two groups. It will be measured in nanograms/ml.	Baseline to 7 days.